
Keywords: AE; adverse event; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; EGFR; epidermal growth factor receptor; FAK; focal adhesion kinase; IGFR; insulin growth factor receptor; MPM; malignant pleural mesothelioma; MTD; maximum tolerated dose; mTOR; mamma